Bronchopulmonary dysplasia (BPD) is a common paediatric disease which causes damage to lung tissue and inhibits normal lung growth in pre-term babies. This often results in impaired neurodevelopment, increased susceptibility to developing respiratory infections and increased hospitalisations, creating a huge burden on both the baby and their family.
However, researchers at the Hudson Institute of Medical Research have recently developed two anti-inflammatory drugs that they believe could prevent the development of BPD. According to senior researcher Dr Ina Rudloff, the drugs have been used previously in other diseases, which will hopefully ensure that they have a safe and effective outcome once clinical trials are over.
Read more here.